Similar articles

• [Osteoporosis and bisphosphonates].

  Zuber MA. Zuber MA. Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8. Z Rheumatol. 2007. PMID: 17955251 German. No abstract available.
• Do not use bisphosphonate therapy indefinitely for fracture prevention.

  [No authors listed] [No authors listed] Prescrire Int. 2008 Oct;17(97):214. Prescrire Int. 2008. PMID: 19536944
• Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

  [No authors listed] [No authors listed] Prescrire Int. 2009 Dec;18(104):247. Prescrire Int. 2009. PMID: 20020572 No abstract available.
• Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

  Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Curr Med Res Opin. 2006 May;22(5):919-28. doi: 10.1185/030079906X100276. Curr Med Res Opin. 2006. PMID: 16709313 Review.
• [Diphosphonate therapy and osteonecrosis of the jaw].

  Løkken P, Skoglund LA, Skjelbred P. Løkken P, et al. Tidsskr Nor Laegeforen. 2007 Aug 9;127(15):1945-7. Tidsskr Nor Laegeforen. 2007. PMID: 17700737 Review. Norwegian. No abstract available.